WO1992004464A3 - Monoclonal antibodies against tenascin - Google Patents
Monoclonal antibodies against tenascin Download PDFInfo
- Publication number
- WO1992004464A3 WO1992004464A3 PCT/US1991/006433 US9106433W WO9204464A3 WO 1992004464 A3 WO1992004464 A3 WO 1992004464A3 US 9106433 W US9106433 W US 9106433W WO 9204464 A3 WO9204464 A3 WO 9204464A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monoclonal antibodies
- antibodies against
- tenascin
- against tenascin
- melanomas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57773290A | 1990-09-05 | 1990-09-05 | |
US577,732 | 1990-09-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1992004464A2 WO1992004464A2 (en) | 1992-03-19 |
WO1992004464A3 true WO1992004464A3 (en) | 2004-05-13 |
Family
ID=24309942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/006433 WO1992004464A2 (en) | 1990-09-05 | 1991-09-05 | Monoclonal antibodies against tenascin |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU8547291A (en) |
WO (1) | WO1992004464A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5436132A (en) * | 1993-02-13 | 1995-07-25 | Amano Pharmaceutical Co., Ltd. | Quantitative determination of tenascin as glioma marker |
US6482410B1 (en) * | 1994-09-16 | 2002-11-19 | The Scripps Research Institute | Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making same |
IT1307864B1 (en) * | 1999-04-20 | 2001-11-19 | Istituto Naz Per La Ricerca Su | DIAGNOSTIC METHOD FOR THE RECOGNITION OF HUMAN NEOPLASIA THROUGH THE DETERMINATION OF THE CTN-C ISOFORM OF TN-C, FRAGMENTS OF |
US20020187100A1 (en) * | 2000-12-21 | 2002-12-12 | David Rizzieri | Anti-tenascin monoclonal antibody therapy for lymphoma |
GB0207224D0 (en) | 2002-03-27 | 2002-05-08 | Novartis Forschungsstiftung | Tenascin-W compositions and uses thereof |
-
1991
- 1991-09-05 WO PCT/US1991/006433 patent/WO1992004464A2/en active Application Filing
- 1991-09-05 AU AU85472/91A patent/AU8547291A/en not_active Abandoned
Non-Patent Citations (9)
Also Published As
Publication number | Publication date |
---|---|
AU8547291A (en) | 1992-03-30 |
WO1992004464A2 (en) | 1992-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL300142I2 (en) | Monoclonal antibody against a cytotoxin, hybridoma cell line, which expresses that and method for the preparation of the purified cytotoxin. | |
IT8319234A0 (en) | PROCEDURE FOR THE PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES. | |
ES2106195T3 (en) | IGG AGLYCOSILATED ANTIBODY ANTI CD3. | |
DE3167698D1 (en) | Method for the determination of antigens with the aid of two or more monoclonal antibodies | |
FI963004L (en) | Monoclonal antibodies that stimulate antibody formation | |
AU1964883A (en) | Monoclonal antibody immunoassay | |
EP0636029A4 (en) | Antibodies specific for carcinoma-associated antigens. | |
DK0724456T3 (en) | CD40 antibodies | |
AU4042195A (en) | Anti-alphaV-integrin monoclonal antibody | |
EP0249007A3 (en) | A method of screening hybridomas | |
HK1015282A1 (en) | High affinity human monoclonal antibodies specificfor rsv f-protein. | |
IT8320550A0 (en) | PERAFFINITY PURIFICATION PROCEDURE IN WHICH MONOCLONAL ANTIBODIES ARE USED. | |
DE3854502D1 (en) | AGAINST HIV-ANTIGENT SPECIFIC MONOCLONAL ANTIBODIES. | |
ITRM920457A0 (en) | MONOCLONAL ANTIBODIES THAT RECOGNIZE AN EPITOPE OF THE HUMAN P-GLYCOPROTEIN. | |
AU4485493A (en) | Method for generating monoclonal antibodies from rabbits | |
DE3885355D1 (en) | Monoclonal antibodies. | |
FI853395A7 (en) | Monoclonal antibodies that block gram-negative bacterial endotoxin. | |
ES551495A0 (en) | PROCEDURE FOR OBTAINING A REACTIVE MONOCLONAL ANTIBODY WITH ESPOROZOITE OR MEROZOIT ANTIGENS FROM EIMERIA SPP. | |
PT840620E (en) | IL-8 ANTAGONISTS FOR ASTHMA TREATMENT | |
WO1992004464A3 (en) | Monoclonal antibodies against tenascin | |
AU1423892A (en) | Monoclonal antibodies directed towards mycobacterial antigens | |
AU2596397A (en) | Monoclonal antibody that detects apoptotic antigen | |
NO20004251D0 (en) | Humanized anti-CEA high affinity monoclonal antibodies | |
DE3785795D1 (en) | MONOCLONAL ANTI-HUMAN CANCER ANTIBODIES. | |
AU3552689A (en) | Monoclonal antibody for colorectal carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/2-2/2,DRAWINGS,REPLACED BY NEW PAGES 1/2-2/2;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |